Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06218914

Title field or adapter rule

{'original_value': 'Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:24.903537+00:00

Published At

2026-09-25T00:00:00+00:00

Record Updated At

2026-09-25

Source Retrieved At

2026-10-31T22:17:54.613222+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-small Cell Lung Cancer", "Colorectal Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Endometrial Cancer", "Solid Tumor, Adult", "KRAS G12D"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-25", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06218914"

protocolSection.identificationModule.officialTitle

"Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Colorectal Carcinoma (protocolSection.conditionsModule.conditions)
• Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Endometrial Cancer (protocolSection.conditionsModule.conditions)
• Solid Tumor, Adult (protocolSection.conditionsModule.conditions)
• KRAS G12D (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['NT-112'], 'description': 'NT-112 targets KRAS G12D in the context of HLA-C\\*08:02', 'name': 'NT-112: Autologous, engineered T Cells targeting KRAS G12D', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['AZD0240'], 'description': 'AZD0240 targets KRAS G12D in the context of HLA-A\\*11:01 or HLA-A\\*11:02', 'name': 'AZD0240: Autologous, engineered T Cells targeting KRAS G12D', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.